(MedPage Today) — CHICAGO — A single infusion of the chimeric antigen receptor (CAR) T-cell therapy ciltacabtagene autoleucel (cilta-cel; Carvykti) improved long-term survival among patients with heavily pretreated relapsed/refractory multiple…
Source link : https://www.medpagetoday.com/meetingcoverage/asco/115892
Author :
Publish date : 2025-06-03 21:30:00
Copyright for syndicated content belongs to the linked Source.
